Kintara Therapeutics is a clinical stage biopharmaceutical company. Co.'s two primary candidates are: VAL-083, a validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer. PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. We show 16 historical shares outstanding datapoints in our coverage of KTRA's shares outstanding history.
Understanding the changing numbers of KTRA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like KTRA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching KTRA by allowing them to research KTRA shares outstanding history
as well as any other stock in our coverage universe. |
Free KTRA Email Alerts:
Video: Shares Outstanding Importance
